Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6282185

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.c1ccc2[nH]c(SCCN3CCNCC3)nc2c1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.60
GRIN2A Q12879 2/20 0.57
GRIN2B Q13224 2/20 0.57
TNKS O95271 1/20 0.53
PARP1 P09874 1/20 0.53
TNKS2 Q9H2K2 1/20 0.53
PARP2 Q9UGN5 1/20 0.53
SOAT1 P35610 5/20 0.52
BCHE P06276 1/20 0.50
GRIN2C Q14957 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 1/20 0.49
EPHX2 P34913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704979 0.89 RAB9A (0.74) RAB9AGRIN2AGRIN2BTNKSPARP1
Hydrochloric Acid SCHEMBL1704951 0.88 RAB9A (0.73) RAB9AGRIN2AGRIN2BTNKSPARP1
Trifluoroacetic Acid SCHEMBL5384259 0.87 ALDH1A1 (0.45) RAB9AGRIN2AGRIN2BTNKSPARP1
Trifluoroacetic Acid SCHEMBL5384262 0.87 ALDH1A1 (0.45) RAB9AGRIN2AGRIN2BTNKSPARP1
SCHEMBL4508692 0.84 RAB9A (0.65) RAB9AGRIN2AGRIN2BTNKSPARP1
Trifluoroacetic Acid SCHEMBL1704549 0.84 ALDH1A1 (0.49) RAB9AGRIN2AGRIN2BTNKSPARP1
SCHEMBL4500584 0.80 RAB9A (0.56) RAB9AGRIN2AGRIN2BTNKSPARP1
SCHEMBL9512664 0.79 RAB9A (0.78) RAB9AGRIN2AGRIN2BTNKSPARP1
SCHEMBL4500580 0.79 RAB9A (0.55) RAB9AGRIN2AGRIN2BTNKSPARP1
SCHEMBL13617010 0.78 RAB9A (0.73) RAB9AGRIN2AGRIN2BTNKSPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969711-B2 Cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2005-11-29 US disclosed
EP-0987254-B1 NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME KOWA CO (JP) 2004-12-22 EP disclosed
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2004-02-26 US disclosed
EP-0987254-A1 NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same LCAT, ACAT2, ACAT1 RAB9A 4712/4885GRIN2A 2525/4885GRIN2B 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.